CD274 and liver cancer: The regulatory role of the miR-133a-3p/MSN/PD-L1 signalling axis was confirmed through flow cytometry, Western blotting, qRT-PCR, and dual-luciferase reporter assays, providing a novel target for liver cancer immunotherapy.